DESIGN OF SYNTHETIC BRANCHED-CHAIN POLYPEPTIDES AS CARRIERS FOR BIOACTIVE MOLECULES

被引:52
作者
HUDECZ, F
机构
[1] Res. Group for Peptide Chemistry, Hungarian Academy of Science, Eotvos L University, H-1518 Budapest 112
关键词
ANTITUMOR AGENT; BRANCHED-CHAIN POLYPEPTIDE; CARRIER; CONJUGATE;
D O I
10.1097/00001813-199504000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
New groups of synthetic biodegradable branched chain polypeptides have been prepared with the general formula poly[Lys-(X(i)DL-Ala(m))] [XAK] or poly[Lys-(DL-Ala(m)-X(i))] [AXK], where m similar to 3 and i < 1, and used to elucidate structural and functional properties required for the selection of macromolecular carriers for (i) targeting/delivery of antitumor agents (e.g. daunomycin, methotrexate, boron derivatives), peptide hormones (e.g. GnRH antagonist) or radionuclides for imaging (e.g. I-123, In-111 Cr-51) or therapy (e.g. Sm-153, I-131) or (ii) the construction of synthetic antigens with peptide epitopes of mucin or Herpes Simplex virus glycoprotein D. Principles applicable for a rational carrier design are outlined based on chemical (size, charge, solution conformation) and biological (cytotoxicity, pirogenicity, biodegradation, immunogenicity, immunomodulatory potential, biodistribution) characterization of these biopolymers and their conjugates.
引用
收藏
页码:171 / 193
页数:23
相关论文
共 101 条
[1]   CONFORMATIONAL ASPECTS OF POLYPEPTIDE STRUCTURE .34. AMINO ACID SUBSTITUTED POLY-L-LYSINES [J].
ANAND, N ;
MURTHY, NSR ;
NAIDER, F ;
GOODMAN, M .
MACROMOLECULES, 1971, 4 (05) :564-&
[2]  
ARNOLD LJ, 1985, METHOD ENZYMOL, V112, P270
[3]   ANTI-NEOPLASTIC ACTIVITY OF POLY(L-LYSINE) WITH SOME ASCITES TUMOR-CELLS [J].
ARNOLD, LJ ;
DAGAN, A ;
GUTHEIL, J ;
KAPLAN, NO .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (07) :3246-3250
[4]  
BARTH RF, 1986, HYBRIDOMA S1, V15, pS43
[5]  
BARTH RF, 1982, CANCER DETECT PREV, V47, P511
[6]  
BERMAN JM, 1983, PEPTIDES STRUCTURE F, P283
[7]   HIGHER ANTI-TUMOR EFFICACY OF DAUNOMYCIN WHEN LINKED TO DEXTRAN - INVIVO AND INVITRO STUDIES [J].
BERNSTEIN, A ;
HURWITZ, E ;
MARON, R ;
ARNON, R ;
SELA, M ;
WILCHEK, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1978, 60 (02) :379-384
[8]   LABELING OF PROTEINS TO HIGH SPECIFIC RADIOACTIVITIES BY CONJUGATION TO A I-125-CONTAINING ACYLATING AGENT - APPLICATION TO RADIOIMMUNOASSAY [J].
BOLTON, AE ;
HUNTER, WM .
BIOCHEMICAL JOURNAL, 1973, 133 (03) :529-538
[9]  
CHU BCF, 1977, MOL PHARMACOL, V13, P80
[10]   DIFFERENTIAL TOXICITY OF CARRIER-BOUND METHOTREXATE TOWARD HUMAN-LYMPHOCYTES, MARROW AND TUMOR-CELLS [J].
CHU, BCF ;
HOWELL, SB .
BIOCHEMICAL PHARMACOLOGY, 1981, 30 (18) :2545-2552